COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT

综合癌症中心核心支持拨款

基本信息

批准号：
9266003
负责人：
EDWARD E. PARTRIDGE
金额：
$ 12.5万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-03-28 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9266003
关键词：
Address African American Age Alabama Animal Model Antibodies Antibody Specificity Apoptotic Area Arkansas Award B-Lymphocytes Behavior Behavior Therapy Biological Markers Biology Body Weight Brain Neoplasms Cancer Center Cancer Survivor Cancer Vaccines Catchment Area Cellular biology Chemopreventive Agent Clinic Clinical Clinical Trials Collaborations Comprehensive Cancer Center Deep South Detection Development Diagnosis Diagnostic Diet Disease Disease Progression Doctor of Medicine Doctor of Philosophy Early Diagnosis Faculty Functional Imaging Funding Gene Expression Genomic Instability Genotype Goals Grant Health Services Accessibility Heart Human Imaging technology Immune system Immunobiology Immunological Diagnosis Immunology Immunotherapeutic agent Immunotherapy Incidence Individual Industry Inflammation Institutes Interdisciplinary Study Intervention Investigation Investigational Therapies Knowledge Laboratories Link Louisiana Malignant Neoplasms Malignant neoplasm of brain Malignant neoplasm of pancreas Mediating Mission Mississippi Modality Molecular and Cellular Biology Morbidity - disease rate Neoplasm Metastasis Obesity Outcome Outcomes Research Pathogenesis Pathology Pathway interactions Patients Peer Review Pharmaceutical Preparations Phase Phenotype Physical activity Population Pre-Clinical Model Prediction of Response to Therapy Predisposition Prevention Public Health Publications Quality of life Radiation Oncology Radioisotopes Recording of previous events Research Risk Scientist Signal Transduction Solid Neoplasm Stimulus Systems Biology T-Lymphocyte Testing Therapeutic Tobacco use Translating Translational Research Translations United States National Institutes of Health Universities Vision Work biomarker identification cancer biomarkers cancer cell cancer health disparity cancer risk cancer stem cell carcinogenesis comparative effectiveness dietary manipulation drug development drug discovery end of life energy balance high risk improved innovation inter-institutional leukemia/lymphoma malignant breast neoplasm member mortality novel novel therapeutic intervention outcome forecast preclinical study predicting response prevent programs research study response screening stem cell therapy success survivorship treatment response tumor tumor immunology tumor microenvironment tumor progression vaccine development virology working group

项目摘要

DESCRIPTION (provided by applicant): Decades of research on basic immunology and the interactions of tumors and the immune system have led over the past few years to an explosive increase in the successes of immunotherapeutic modalities in cancer. The objective of the Inflammation, Immunology, and Immunotherapeutics (III) Program is to build on and to accelerate those successes by developing novel therapeutic approaches for the treatment of leukemia/lymphoma and solid tumors, and to understand and exploit the basic biology of the immune system's responses to cancers. The emphasis is on antibody and T-cell mediated therapy in preclinical models and clinical translation studies. The Tumor Immunology Program has been a component of the Cancer Center since its inception and in 2012, it merged with the Virology Program to become the III Program. It is currently led by Casey T. Weaver, M.D. (Pathology), and Donald J. Buchsbaum, Ph.D. (Radiation Oncology), and has 40 primary faculty members from seven departments. The Program has $11,611,410 in annual direct grant support of cancer relevant research including $756,267 from NCI, $9,592,968 from other NIH Institutes, $289,001 from other peer-reviewed awards, and $973,174 in non-peer-reviewed support. The Program has two major areas of emphasis: (1) development of targeted immunotherapy utilizing antibody specificity to deliver apoptotic stimuli, drugs, or radioactive isotopes to tumors in animal models and human cancer; and (2) exploration of basic immunobiology research in the areas of inflammation and T- and B-cell immunology to translate into immunodiagnostic and immunotherapeutic modalities. The Program has major collaborations with the Experimental Therapeutics and Cancer Cell Biology Programs, and HudsonAlpha including individual projects in the Breast Cancer and Pancreatic Cancer SPOREs. During the previous funding period there were 310 total publications, of which 72 (23%) were intra-programmatic, 69 (22%) inter-programmatic, and 161 (52%) inter-institutional.

描述（由申请人提供）：过去几年，对基础免疫学以及肿瘤和免疫系统相互作用的数十年研究导致癌症免疫治疗方式的成功率呈爆炸性增长。和免疫治疗 (III) 计划旨在通过开发治疗白血病/淋巴瘤和实体瘤的新治疗方法来巩固和加速这些成功，并了解和利用免疫系统对癌症反应的基本生物学原理，重点是临床前模型和临床转化研究中的抗体和 T 细胞介导的治疗，自 2012 年成立以来，肿瘤免疫学项目一直是癌症中心的组成部分。它与病毒学项目合并成为 III 项目，目前由医学博士 Casey T. Weaver（病理学）和 Donald J. Buchsbaum 博士（辐射学）领导。该计划拥有来自七个部门的 40 名主要教职人员，每年为癌症相关研究提供 11,611,410 美元的直接拨款支持，其中包括来自 NCI 的 756,267 美元、来自其他 NIH 研究所的 9,592,968 美元、来自其他同行评审奖项的 289,001 美元以及来自非同行评审的 973,174 美元。该计划有两个重点领域：(1) 发展。利用抗体特异性向动物模型和人类癌症中的肿瘤提供细胞凋亡刺激、药物或放射性同位素的靶向免疫疗法；(2) 探索炎症和 T 细胞和 B 细胞免疫学领域的基础免疫生物学研究，并将其转化为该计划与实验治疗和癌细胞生物学计划以及 HudsonAlpha 进行了重大合作，包括乳腺癌和胰腺癌孢子领域的个别项目。在上一资助期间，共有 310 份出版物，其中 72 份 (23%) 为计划内出版物，69 份 (22%) 为计划间出版物，161 份 (52%) 为机构间出版物。